search
Back to results

The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Randomized Controlled Trial

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 3
Locations
Netherlands
Study Type
Interventional
Intervention
Metformin on top of intensive insulin therapy
Sponsored by
Bethesda General Hospital, Hoogeveen
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Type 2 diabetes mellitus, Metformin on top of insulin therapy, Randomized placebo-controlled trial, Diabetes regulation, Daily dose of insulin, Body Weight, Patients with type 2 diabetes, Intensive insulin therapy, Age: 30-80 years, Body mass index, Lipids, Blood Pressure, Endothelial function, Low grade inflammation, Fibrinolysis, Microvascular complications, Macrovascular complications

Eligibility Criteria

30 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients of both sexes (women after menopause, women of child-bearing age after sterilization or if practicing reliable contraception)
  • Type 2 DM requiring insulin therapy after failure of maximal oral antidiabetic treatment (glycosylated Hb > 7.5%) and need for exogenous insulin. (No concomitant use of oral antidiabetic agents)
  • Being ambulatory
  • Age: 30 to 80 years
  • Proven absence of Islet Antibodies, if QI < 28 kg/m2
  • Insulin therapy 4 times daily (21), or insulin therapy 2 times daily using insulin 'mixtures' (rapidly and slowly acting)
  • Standard dietary prescription by the dietician
  • Absence of keto-acidosis
  • Informed consent

Exclusion Criteria:

  • Congestive heart failure, NYHA-classes III or IV
  • Cardiac failure and/or myocardial infarction in the last four months before enrolment
  • Other severe organic / systemic disease
  • Metformin-induced lactic-acidosis
  • Intolerance to metformin hydrochloride
  • Renal disease or renal dysfunction
  • Hypoxic states
  • Severe hepatic dysfunction
  • Excessive alcohol intake, acute or chronic
  • Acute or chronic metabolic acidosis

Sites / Locations

  • Bethesda General Hospital and Bethesda Diabetes Center

Outcomes

Primary Outcome Measures

To investigate the quality of the metabolic control of diabetes and related variables (daily dose of insulin, body weight).

Secondary Outcome Measures

To investigate the occurrence and progression of macro- and microvascular complications.
To investigate the quality of life.
To perform a socio-economic evaluation.

Full Information

First Posted
September 12, 2006
Last Updated
September 12, 2006
Sponsor
Bethesda General Hospital, Hoogeveen
Collaborators
Takeda, LifeScan, Merck KGaA, Darmstadt, Germany, Dupont Merck, Merck Sharp & Dohme LLC, Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT00375388
Brief Title
The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Randomized Controlled Trial
Official Title
Study of Metformin HCL in Patients With Type 2 Diabetes Intensively Treated With Insulin: a Treatment Strategy for Insulin Resistance in Type 2 Diabetes Mellitus: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2006
Overall Recruitment Status
Completed
Study Start Date
January 1998 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
October 2002 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Bethesda General Hospital, Hoogeveen
Collaborators
Takeda, LifeScan, Merck KGaA, Darmstadt, Germany, Dupont Merck, Merck Sharp & Dohme LLC, Novo Nordisk A/S

4. Oversight

5. Study Description

Brief Summary
The HOME-trial is a prospective, randomized controlled trial. The purpose of this study is to investigate the effects of metformin HCL in patients with type 2 diabetes mellitus intensively treated with insulin on the quality of the metabolic control of diabetes, the daily dose of insulin, the lipid profile, the blood pressure, the incidence / progression of microvascular and macrovascular complications, and on the qualify of life (Diabetes Health Profile). Early results had been published in Diabetes Care, December 2002, pages 2133-2140.
Detailed Description
The HOME-trial is a prospective, randomized controlled trial. The purpose of this study is to investigate the effects of metformin HCL in patients with type 2 diabetes mellitus intensively treated with insulin on the quality of the metabolic control of diabetes, the daily dose of insulin, the lipid profile, the blood pressure, the incidence / progression of microvascular and macrovascular complications, and on the qualify of life (Diabetes Health Profile). Early results had been published in Diabetes Care, December 2002, pages 2133-2140. Phase: Phase III Study Type: Interventional Overall Status: No longer recruiting (all patients have finished the study) Study Start Date 02 January 1998 Study Completion Date October 2002 Study Design: Study Purpose: Treatment Allocation: 1 randomized 0 non randomized Masking: Double blind Control: Placebo Assignment: Parallel Endpoints: Safety / Efficacy Primary Outcome: • To investigate the quality of the metabolic control of diabetes and related variables (daily dose of insulin, body weight). Secondary Outcome: To investigate the occurrence of macro- and microvascular complications. To investigate the quality of life and to perform a socio-economic evaluation. Conditions: Type 2 diabetes mellitus requiring insulin therapy. Keywords: Type 2 diabetes mellitus; metformin; randomized; double-blind; placebo-controlled; diabetes regulation Interventions: Metformin (850 mg) or placebo 1-3 times daily. Insulin: 4 times daily or 'mixtures' of 30% rapidly and 70% slowly acting insulin, 2 times daily. Eligibility Criteria (only add main ones) Inclusion Criteria: Patients of both sexes (women after menopause, women of child-bearing age after sterilization or if practicing reliable contraception) Type 2 DM requiring insulin therapy after failure of maximal oral antidiabetic treatment (glycosylated Hb > 7.5%) and need for exogenous insulin. (No concomitant use of oral antidiabetic agents) Being ambulatory Age: 30 to 80 years Proven absence of Islet Antibodies, if QI < 28 kg/m2 Insulin therapy 4 times daily (21), or insulin therapy 2 times daily using insulin 'mixtures' (rapidly and slowly acting) Standard dietary prescription by the dietician Absence of keto-acidosis Informed consent Exclusion Criteria: Congestive heart failure, NYHA-classes III or IV Cardiac failure and/or myocardial infarction in the last four months before enrolment Other severe organic / systemic disease Metformin-induced lactic-acidosis Intolerance to metformin hydrochloride Renal disease or renal dysfunction Hypoxic states Severe hepatic dysfunction Excessive alcohol intake, acute or chronic Acute or chronic metabolic acidosis Gender: Both Age: 30 - 80 years Target Number of Subjects: 400 (200 metformin, 200 placebo) Central Contact: Name: Adriaan Kooy , internist - diabetologist Degree: MD, PhD Phone: 0528-286222 Extension: 624 Mail: kooy.a@bethesda.nl Study Official/ Investigators Name: Adriaan Kooy Degree: MD, PhD Officials Role: Study Principal Investigator Organizational Affiliation: Bethesda Hospital Hoogeveen Dr. G.H. Amshoffweg 1 7909 AA Hoogeveen The Netherlands Locations: Facility: Bethesda Hospital Hoogeveen City: Hoogeveen State/Province: Drenthe Country: The Netherlands Recruitment Status: No longer recruiting (all patients finished) Facility: Diaconesses' Hospital Meppel City: Meppel State/Province: Drenthe Country: The Netherlands Recruitment Status: No longer recruiting (all patients finished) Facility: Hospital Coevorden - Hardenberg City: Coevorden State/Province: Drenthe Country: The Netherlands Recruitment Status: No longer recruiting (all patients finished)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Type 2 diabetes mellitus, Metformin on top of insulin therapy, Randomized placebo-controlled trial, Diabetes regulation, Daily dose of insulin, Body Weight, Patients with type 2 diabetes, Intensive insulin therapy, Age: 30-80 years, Body mass index, Lipids, Blood Pressure, Endothelial function, Low grade inflammation, Fibrinolysis, Microvascular complications, Macrovascular complications

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
400 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Metformin on top of intensive insulin therapy
Primary Outcome Measure Information:
Title
To investigate the quality of the metabolic control of diabetes and related variables (daily dose of insulin, body weight).
Secondary Outcome Measure Information:
Title
To investigate the occurrence and progression of macro- and microvascular complications.
Title
To investigate the quality of life.
Title
To perform a socio-economic evaluation.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients of both sexes (women after menopause, women of child-bearing age after sterilization or if practicing reliable contraception) Type 2 DM requiring insulin therapy after failure of maximal oral antidiabetic treatment (glycosylated Hb > 7.5%) and need for exogenous insulin. (No concomitant use of oral antidiabetic agents) Being ambulatory Age: 30 to 80 years Proven absence of Islet Antibodies, if QI < 28 kg/m2 Insulin therapy 4 times daily (21), or insulin therapy 2 times daily using insulin 'mixtures' (rapidly and slowly acting) Standard dietary prescription by the dietician Absence of keto-acidosis Informed consent Exclusion Criteria: Congestive heart failure, NYHA-classes III or IV Cardiac failure and/or myocardial infarction in the last four months before enrolment Other severe organic / systemic disease Metformin-induced lactic-acidosis Intolerance to metformin hydrochloride Renal disease or renal dysfunction Hypoxic states Severe hepatic dysfunction Excessive alcohol intake, acute or chronic Acute or chronic metabolic acidosis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Adriaan Kooy, MD, PhD
Organizational Affiliation
Bethesda General Hospital and Bethesda Diabetes Center, Hoogeveen, The Netherlands (for address: see above)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Coen Stehouwer, MD, PhD
Organizational Affiliation
University Hospital of Maastricht, The Netherlands
Official's Role
Study Director
Facility Information:
Facility Name
Bethesda General Hospital and Bethesda Diabetes Center
City
Hoogeveen
State/Province
Drenthe
ZIP/Postal Code
7909 AA
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
12453950
Citation
Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care. 2002 Dec;25(12):2133-40. doi: 10.2337/diacare.25.12.2133.
Results Reference
result
PubMed Identifier
35379238
Citation
Stultiens JMG, Top WMC, Kimenai DM, Lehert P, Bekers O, Stehouwer CDA, Kooy A, Meex SJR. Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a post-hoc analysis of a randomized controlled trial. Cardiovasc Diabetol. 2022 Apr 4;21(1):49. doi: 10.1186/s12933-022-01482-z.
Results Reference
derived
PubMed Identifier
29790415
Citation
Out M, Becker ML, van Schaik RH, Lehert P, Stehouwer CD, Kooy A. A gene variant near ATM affects the response to metformin and metformin plasma levels: a post hoc analysis of an RCT. Pharmacogenomics. 2018 Jun 1;19(8):715-726. doi: 10.2217/pgs-2018-0010. Epub 2018 May 23.
Results Reference
derived
PubMed Identifier
29667290
Citation
Out M, Top WMC, Lehert P, Schalkwijk CA, Stehouwer CDA, Kooy A. Long-term treatment with metformin in type 2 diabetes and vitamin D levels: A post-hoc analysis of a randomized placebo-controlled trial. Diabetes Obes Metab. 2018 Aug;20(8):1951-1956. doi: 10.1111/dom.13327. Epub 2018 May 14.
Results Reference
derived
PubMed Identifier
29174300
Citation
Out M, Kooy A, Lehert P, Schalkwijk CA, Stehouwer CDA. Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: Post hoc analysis of a randomized controlled 4.3year trial. J Diabetes Complications. 2018 Feb;32(2):171-178. doi: 10.1016/j.jdiacomp.2017.11.001. Epub 2017 Nov 8.
Results Reference
derived
PubMed Identifier
28681986
Citation
Out M, Miedema I, Jager-Wittenaar H, van der Schans C, Krijnen W, Lehert P, Stehouwer C, Kooy A. Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial. Diabetes Obes Metab. 2018 Jan;20(1):219-223. doi: 10.1111/dom.13054. Epub 2017 Sep 14.
Results Reference
derived
PubMed Identifier
20488910
Citation
de Jager J, Kooy A, Lehert P, Wulffele MG, van der Kolk J, Bets D, Verburg J, Donker AJ, Stehouwer CD. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010 May 20;340:c2181. doi: 10.1136/bmj.c2181.
Results Reference
derived
PubMed Identifier
19307526
Citation
Kooy A, de Jager J, Lehert P, Bets D, Wulffele MG, Donker AJ, Stehouwer CD. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009 Mar 23;169(6):616-25. doi: 10.1001/archinternmed.2009.20.
Results Reference
derived

Learn more about this trial

The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Randomized Controlled Trial

We'll reach out to this number within 24 hrs